Precisely Engineered Block Copolymers for Efficient PTEN mRNA Therapy of Non-Small Cell Lung Cancer
ACS Applied Materials & Interfaces · 05.08.2026 · 18 (30) · 40505-40519
DOI: 10.1021/acsami.6c10662 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 24.07.2026. Verfasst von Hongyang Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: State-Key Laboratory of Chemical Engineering, and Shanghai Key Laboratory of Multiphase Materials Chemical Engineering, East China University of Scie…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, PTEN Phosphohydrolase, RNA, Messenger, Lung Neoplasms. Die Arbeit nennt 62 Literaturangaben. Gefördert von: State Administration of Foreign Experts Affairs, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Restoring the tumor suppressor PTEN (phosphatase and tensin homolog) offers a promising therapeutic strategy for nonsmall cell lung cancer (NSCLC). In particular, mRNA-based therapy provides a compelling alternative to small molecules and DNA-based gene therapy, combining high specificity with an excellent safety profile. However, its clinical translation hinges on the development of safe and efficient delivery systems. In this study, we present a rationally designed diblock copolymer that mediates highly effective PTEN mRNA delivery both in vitro and in vivo. The copolymer consists of a stealth PEG block and a cationic binding block, with precisely engineered 3-acrylamidophenylboronic acid (AAPBA) and N-(3-dimethylaminopropyl) methacrylamide (DMAPMA) units. Following optimization of the PEG chain length, the structure PEG45-b-P(AAPBA21-co-DMAPMA18) achieved a critical balance of delivery properties, leading to enhanced cellular uptake, facilitated endosomal escape, and enabled mRNA release for protein translation. When further functionalized with folic acid (FA), the copolymer successfully restored PTEN expression and inhibited tumor growth (81.0% relative to the PBS control group) in vivo, with no significant toxicity observed under the tested conditions. We anticipate that this block copolymer-based PTEN mRNA delivery platform could provide a promising new approach for the treatment of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State-Key Laboratory of Chemical Engineering, and Shanghai Key Laboratory of Multiphase Materials Chemical Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, People's Republi…
- Department of Respiratory and Critical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai200233, People's Republic of China.
ORCID-Profile: Martien A Cohen Stuart, Junyou Wang
Förderung
- State Administration of Foreign Experts Affairs
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Shanghai Sixth People's Hospital
Zitieren
APA
Zhao, H., Zhang, S., Tian, C., Li, L., Qiu, Y., Yu, Y., Cohen Stuart, M. A., Wang, J., & Lu, Y. (2026). Precisely Engineered Block Copolymers for Efficient PTEN mRNA Therapy of Non-Small Cell Lung Cancer. ACS Applied Materials & Interfaces, 18(30), 40505-40519. https://doi.org/10.1021/acsami.6c10662
Vancouver
Zhao H, Zhang S, Tian C, Li L, Qiu Y, Yu Y, et al. Precisely Engineered Block Copolymers for Efficient PTEN mRNA Therapy of Non-Small Cell Lung Cancer. ACS Applied Materials & Interfaces. 2026;18(30):40505-40519. doi:10.1021/acsami.6c10662
BibTeX
@article{Zhao2026,
author = {Zhao, Hongyang and Zhang, Shiting and Tian, Chang and Li, Lingshu and Qiu, Yuening and Yu, Yilei and Cohen Stuart, Martien A and Wang, Junyou and Lu, Yi},
title = {Precisely Engineered Block Copolymers for Efficient PTEN mRNA Therapy of Non-Small Cell Lung Cancer},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
volume = {18},
number = {30},
pages = {40505--40519},
doi = {10.1021/acsami.6c10662}
}
EUVIMED